Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2011 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Cariprazine Orodispersible Tablet: A New Formulation for Cariprazine.
Meszár V, Magyar G, Pásztor GM, Szatmári B, Péter K, Marton L, Dombi ZB, Barabássy Á. Meszár V, et al. Among authors: pasztor gm. Pharmacopsychiatry. 2024 May 6. doi: 10.1055/a-2291-7130. Online ahead of print. Pharmacopsychiatry. 2024. PMID: 38710207 Free article.
Occupancy of dopamine D₂ and D₃ and serotonin 5-HT₁A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography.
Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B. Seneca N, et al. Among authors: pasztor g. Psychopharmacology (Berl). 2011 Dec;218(3):579-87. doi: 10.1007/s00213-011-2343-z. Epub 2011 May 28. Psychopharmacology (Berl). 2011. PMID: 21625907 Free PMC article.
Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents.
Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor EÁ, Domány G, Tihanyi K, Szombathelyi Z. Gyertyán I, et al. Among authors: pasztor g. Neurochem Int. 2011 Nov;59(6):925-35. doi: 10.1016/j.neuint.2011.07.002. Epub 2011 Jul 13. Neurochem Int. 2011. PMID: 21767587
Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.
Gyertyán I, Sághy K, Laszy J, Elekes O, Kedves R, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Agai Csongor E, Domány G, Kiss B, Szombathelyi Z. Gyertyán I, et al. Among authors: pasztor g. Naunyn Schmiedebergs Arch Pharmacol. 2008 Nov;378(5):529-39. doi: 10.1007/s00210-008-0311-x. Epub 2008 Jun 12. Naunyn Schmiedebergs Arch Pharmacol. 2008. PMID: 18548231
Effects of RGH-237 [N-{4-[4-(3-aminocarbonyl-phenyl)-piperazin-1-yl]-butyl}-4-bromo-benzamide], an orally active, selective dopamine D(3) receptor partial agonist in animal models of cocaine abuse.
Gyertyán I, Kiss B, Gál K, Laszlovszky I, Horváth A, Gémesi LI, Sághy K, Pásztor G, Zájer M, Kapás M, Csongor EA, Domány G, Tihanyi K, Szombathelyi Z. Gyertyán I, et al. Among authors: pasztor g. J Pharmacol Exp Ther. 2007 Mar;320(3):1268-78. doi: 10.1124/jpet.106.107920. Epub 2006 Dec 14. J Pharmacol Exp Ther. 2007. PMID: 17170312